(Reuters) – The risk of hospitalization after vaccination with Johnson & Johnson’s COVID-19 vaccine was about five times higher than for those who received the Pfizer and BioNTech shot, a large French study found.
The study included nearly 7 million recipients of the two-dose mRNA vaccine from Pfizer/BioNTech and an equal number of similar people who received the one-shot vector-based vaccine from J&J. The average age was about 66, and about half were women.
By the time half the participants had been fully vaccinated for at least six weeks, there had been 129 hospitalizations among J&J vaccine recipients versus 23 among the Pfizer/BioNTech group, the researchers reported in JAMA Network Open.
Based on their data, they estimated the effectiveness of the vaccines at preventing hospitalization at 92% for Pfizer’s shots versus 59% for the J&J vaccine.
“These results strengthen the evidence” in favor of giving an mRNA booster shot to people who initially received the J&J vaccine, the authors conclude.
SOURCE: https://bit.ly/3C69p0C JAMA Network Open, online March 2, 2022.